Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT06008080

Post-Market Clinical Follow Up Study With Navitor Valve

Post-Market Clinical Follow Up Study With Navitor Valve — Recruiting • Cardiology / Cardiovascular • NCT06008080.

📅 10 Jul 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT06008080
Sponsor
Abbott Medical Devices
Start
2023-09-29
ClinicaliQ Trial Snapshot
  • Post-Market Clinical Follow Up Study With Navitor Valve — Recruiting • Cardiology / Cardiovascular • NCT06008080.
  • What is being tested: The Navitor TAVI (Transcatheter Aortic Valve Implantation) System is undergoing post-market evaluation to assess its safety profile and clinical performance in real-world patient populations following commercial approval.
  • Patient eligibility overview: The study includes patients with aortic valve disease who are candidates for transcatheter aortic valve replacement, with eligibility determined by standard TAVI assessment criteria and participating centre protocols across the global study sites.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Evaluation of the safety and performance of the Navitor TAVI System in a Global Study

Eligibility Snapshot
  • : * Patient is eligible per the current approved indication after Heart Team discussion and intended to undergo a Navitor TAVI procedure. * The patient has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent as approved by the IRB (Investigational Review Board)/EC (Ethics Committee) of the respective clinical site. * The patient and the treating physician agree that the subject will return for all required post procedure follow up visits.

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Aortic Valve Disease: TAVI and Surgical Replacement (NICE TA631)
Cardiology / Cardiovascular · 27 Mar 2026
Offer TAVI as first-line intervention for symptomatic aortic stenosis in patients at high or prohibitive surgical risk, or with severe comorbidities precluding…
View guideline →
Guideline
Artificial intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: early-use assessment
Cardiology / Cardiovascular · 19 May 2026
AI-assisted echocardiography can support faster preliminary analysis and reporting of echo images in heart failure patients, potentially reducing reporting delays and improving…
View guideline →
Guideline
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
Cardiology / Cardiovascular · 07 May 2026
Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to reduce major adverse cardiovascular events – consider prescribing as part…
View guideline →
Guideline
Netarsudil for treating open-angle glaucoma or ocular hypertension (terminated evaluation)
Cardiology / Cardiovascular · 16 Jul 2026
Netarsudil evaluation by NICE was terminated, indicating it is not recommended for routine use in NHS treatment pathways for open-angle glaucoma or…
View guideline →
Guideline
Finerenone for treating chronic heart failure with preserved or mildly reduced ejection fraction
Cardiology / Cardiovascular · 05 Aug 2026
Finerenone is recommended as an option for chronic heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) and can be initiated…
View guideline →
Clinical Brief
What in the World
Cardiology / Cardiovascular · BBC Health · 07 Jul 2026
Heatwaves pose significant clinical risk, with heatstroke and dehydration representing the primary acute complications requiring recognition and management Healthcare professionals should anticipate…
View brief →